Plant Name: Commelina communis
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; NPSR1; | |
| PTPN1; | |
| ALPI; TDP1; HPGD; AKR1B1; GFER; HSD17B10; TNKS2; TNKS; PARP1; AGL; POLB; | |
| GAA; | |
| CA2; CA1; CA12; CA9; CA7; CA5A; CA3; CA14; CA5B; CA4; CA6; | |
| AR; | |
| ESR2; | |
| MMP9; MMP1; MMP2; | |
| HIF1A; TP53; NFKB1; | |
| FUT7; | |
| LMNA; RAB9A; NPC1; MAPT; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
| Enzyme_unclassified | AGL | Glycogen debranching enzyme | P35573 | CHEMBL5272 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.828E-07 | 2.341E-04 | CYP19A1, CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.046E-07 | 2.475E-04 | CYP1A2, CYP2D6, CYP3A4 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 6.161E-07 | 5.833E-04 | CA2, CA7, HIF1A, NPC1, NPSR1, TNKS, TNKS2 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.237E-27 | 4.870E-23 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.229E-06 | 1.942E-03 | CYP1A2, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.968E-06 | 2.308E-03 | CYP19A1, CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0010038; response to metal ion | 6.069E-06 | 4.004E-03 | CA2, CYP1A2, HIF1A, MMP9, NPC1, PARP1, TP53 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 8.580E-06 | 5.190E-03 | CA2, CA7, HIF1A, NPC1, NPSR1, PARP1, TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 1.450E-05 | 7.894E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.450E-05 | 7.894E-03 | CA2, CA7 |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 1.536E-05 | 7.966E-03 | HPGD, MMP2, MMP9 |
| BP | GO:0009987; cellular process | GO:0033554; cellular response to stress | 1.760E-05 | 8.708E-03 | AKR1B1, CA2, CA9, HIF1A, LMNA, MAPT, MMP9, NFKB1, PARP1, POLB, PTPN1, TDP1, TP53 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.202E-20 | 1.309E-16 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.354E-19 | 8.545E-16 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 9.318E-17 | 2.899E-13 | ALPI, AR, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR2, MMP1, MMP2, MMP9, PARP1, PTPN1, TNKS, TP53 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.379E-26 | 1.600E-24 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.770E-06 | 1.027E-04 | MMP1; MMP2; MMP9; TP53 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 2.004E-05 | 7.748E-04 | AR; MMP1; MMP2; HIF1A; TP53; MMP9; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 2.296E-04 | 6.102E-03 | PARP1; LMNA; TP53; NFKB1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.630E-04 | 6.102E-03 | CYP1A2; CYP3A4; CYP19A1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 4.393E-04 | 8.494E-03 | CYP2D6; CYP1A2; CYP3A4 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 9.329E-04 | 1.073E-02 | MMP2; TP53; HIF1A; MMP9 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 5.184E-04 | 8.591E-03 | CYP2D6; CYP1A2; CYP3A4 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 9.243E-04 | 1.073E-02 | AR; TP53; NFKB1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.084E-03 | 1.073E-02 | FUT7; GAA; AGL; CYP1A2; AKR1B1; ALPI; CYP3A4; CYP19A1; HSD17B10 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 5.954E-04 | 8.633E-03 | HPGD; TP53; MMP9; NFKB1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.258E-03 | 1.122E-02 | MMP2; MMP9; ESR2 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 3.111E-03 | 2.123E-02 | RAB9A; TP53; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 3.798E-03 | 2.448E-02 | TP53; MMP9; NFKB1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 9.690E-03 | 4.628E-02 | POLB; TP53; NFKB1 |
| hsa00500 | Starch and sucrose metabolism_Homo sapiens_hsa00500 | 6.460E-03 | 3.944E-02 | AGL; GAA |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 8.877E-03 | 4.628E-02 | TP53; NFKB1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.767E-03 | 1.462E-02 | CYP1A2; CYP3A4 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.110E-03 | 1.073E-02 | CA2; CA4 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 8.619E-03 | 4.628E-02 | CYP1A2; CYP3A4 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 9.137E-03 | 4.628E-02 | TP53; HIF1A |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.049E-02 | 4.628E-02 | NFKB1; ESR2 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.890E-03 | 1.462E-02 | GAA; AKR1B1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.077E-02 | 4.628E-02 | TP53; NFKB1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.021E-02 | 4.628E-02 | CA2; CYP3A4 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 2.285E-03 | 1.657E-02 | POLB; PARP1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.070E-02 | 4.628E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; MMP2 |
| NA: NA | Male hypogonadism | NA | AR |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR |
| C00-D49: Neoplasms | Melanoma | C43 | PARP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; MMP9 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR |
| C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | PARP1 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; CA9; MMP9; MMP2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; HIF1A; TP53; CA1; CA9; MMP9; NFKB1; MMP2; PARP1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; NFKB1 |
| NA: NA | Edema | NA | CA2 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PARP1 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; PARP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; AKR1B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CYP2D6 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |